Early onset tardive syndromes associated with Lurasidone in patients with mood disorders: A case series and literature review

Abstract

Background: Tardive syndromes are a group of movement disorders that typically occur following chronic exposure to Dopamine D2 receptor antagonists. Rarely, these syndromes may occur in less than six months following the initiation of a causative medication. Owing to Lurasidone's recent introduction to the North American market, there is limited literature on its association with tardive syndromes. Methods: We describe three cases with mood disorders prospectively and systematically followed for tardive syndromes on Lurasidone and present a literature review of existing data on tardive syndromes associated with Lurasidone in patients with mood disorders. Results: These three cases all developed tardive syndromes before three months. A single previously published case series included cases of early-onset tardive syndromes following lurasidone use. Limitations: This is an open case series in a single academic practice focused on mood disorders. There is limited data in the literature for comparison. Discussion: Lurasidone's common use in patients with vulnerabilities to developing tardive syndromes, such as those with mood disorders, may be an area for clinical concern. Clinicians should strongly consider earlier screening for tardive syndromes in patients with appropriate risk factors.

Keywords

• Tardive syndrome
• Dyskinesia
• Mood disorder
• Lurasidone